Skip to main content Skip to search Skip to main navigation

EMA: Public Consultation on Remote Batch Certification

The EMA has published a four-page consultation document in the form of Q&As concerning the physical attendance and the place of a personal residence of a Qualified Person on 11 May 2022. The guidance states that the work of a QP must be adapted to current standards to enable remote certifications without a QP being present at the site. A public consultation is possible until 13 June 2022.

The Q&A is based on the fundamentals of the EU GMP Guidelines, in particular those of Annex 16, and is applicable to EU/EEA QP certification or QP confirmation. It applies to the production and importation of human and veterinary medicinal products as well as investigational medicinal products. Following is a brief summary of the four Q&As:

Is remote batch certification / batch confirmation by the QP (i.e. when not at the authorised site address specified on the MIA) allowed on a routine basis?

This could be acceptable if a remote certification is accepted by the national authority at the site. The manufacturer and the qualified person should meet all valid local requirements.


Where remote QP certification / confirmation is allowed on a routine basis, what conditions should apply?

Broadly summarised, they include

  • full compliance of the remote certification with EU legislation and EU GMP guidelines
  • a certification that must take place within the EU/EEA in any case
  • adequate documentation and control within the quality system when remote certification is used on a routine basis
  • electronic access to any information required for QP according to Annex 16 EU GMP Guidance. All IT systems must comply with the requirements of EU-GMP Annex 11
  • The availability of all performed measurements for inspection purposes by the competent authorities.

Is the QP required to be a resident in the Member State where the authorised site is located?

Reference is made to the specific national requirements


What are the technical requirements for the remote access and the signature used for batch certification / confirmation?

In terms of IT security and data integrity, the risk for remote access is higher than for access within the controlled environment at the approved site. The minimum requirements are highly dependent on the state of the technology and should be consistent with the guidelines of Annex 11. For instance, among other things:

  • Recognized industry standards should be used for authentication and authorization (e.g., two-factor or multi-factor authentication)
  • Security parameters on the network operating system, database, and application layer of the QP should be configured adequately
  • data should be secured using a high-level of transport encryption
  • the MIA holder must ensure that only the QP is able to perform remote certification/confirmation of batches

Source:

EMA: Public Consultation Concerning The Physical Attendance And The Location Of Personal Residency Of The Qualified Person

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ANVISA: Expands Recognition of Foreign GMP Authorities

ANVISA: Expands Recognition of Foreign GMP Authorities

Brazilian health authority ANVISA has updated the requirements for the recognition of Equivalent Foreign Regulatory Authorities (AREE) and the administrative procedures for Good Manufacturing Practice (GMP) certification (CBPF) through Normative Instruction IN 451/2026. The aim is to streamline and accelerate regulatory processes.
Read more
EDQM: Guidance on Reporting on Disappearances of Medicinal Products

EDQM: Guidance on Reporting on Disappearances of Medicinal Products

The EDQM has published guidance supporting the implementation of Recommendation CM/Rec(2024)3 on reporting medicinal products that disappear from the legal supply chain due to theft, loss or diversion. The initiative follows a European survey that identified shortcomings in reporting and co-ordination of such incidents.

Read more
What are the Phases of a Working Cycle During a Steam Sterilisation Process?

What are the Phases of a Working Cycle During a Steam Sterilisation Process?

Here's the answer:
Read more
Damage Control: Complaints and Recalls

Damage Control: Complaints and Recalls

Complaint handling and product recalls are important components of the Pharmaceutical Quality System (PQS). They serve to identify defective medicinal products and ensure that appropriate measures are taken to protect patient safety, as required by law and the competent supervisory authority.

Read more
EMA: 9 New Nitrosamines for Appendix 1

EMA: 9 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

The European Medicines Agency (EMA) published an update to its “Quality of Medicines: Questions and Answers – Part 2”. The revision concerns the section on “Reduced testing of incoming starting materials”.
Read more
Previous
Next